Risk of death 21% lower in patients with HIV-related fungal disease who were given combination drug treatment

A clinical trial conducted in South Africa and Tanzania revealed that patients with HIV-related cryptococcal disease who were treated with a combination of fluconazole and flucytosine had a 21% lower risk of death compared to those who received only fluconazole. The study, presented at the International AIDS Conference 2026 in Brazil, examined the potential of the combination therapy to prevent deaths before meningitis sets in.

The research involved 604 participants with cryptococcal antigen in their blood but no meningitis symptoms. Both treatment groups took fluconazole for two weeks, followed by a lower daily dose for eight weeks. The combination therapy group had a 13% death rate (40 out of 304 people) after six months, while the control group had a 17% death rate (50 out of 300).

Among those who adhered to the treatment consistently, the risk of death was 29% lower in the combination therapy group (13% death rate out of 239 people, compared to an 18% death rate out of 260 in the control group). The results showed a 47% lower risk of death among a subgroup with higher cryptococcal antigen levels. However, the study did not prove that the two-drug combination was responsible for the observed benefit, as a larger study would be needed to confirm the treatment's effectiveness.

The researchers emphasized that the combination therapy was safe and that further implementation studies were needed to determine its effectiveness in real-world settings, particularly in low-resource areas where spinal taps for fungal antigen screening are not feasible.